Artia Global Partners
Latest statistics and disclosures from Artia Global Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are INSM, ABVX, ARGX, LLY, UGL, and represent 58.51% of Artia Global Partners's stock portfolio.
- Added to shares of these 10 stocks: ABVX (+$52M), LLY (+$23M), VKTX (+$20M), CDTX (+$16M), NAMS (+$11M), QURE (+$8.7M), IONS (+$6.7M), VTYX (+$6.3M), PVLA (+$6.2M), SION.
- Started 19 new stock positions in CELC, PVLA, SION, PRAX, ROIV, PEPG, TENX, UPB, PALI, DRUG. PROK, ANRO, KOD, CDTX, NUVL, VTYX, BLTE, AVTX, LYRA.
- Reduced shares in these 10 stocks: VRNA (-$40M), MRUS (-$28M), , BSX (-$18M), ARGX (-$11M), DGX (-$7.1M), ALNY (-$6.8M), RARE (-$6.5M), , INSM (-$5.2M).
- Sold out of its positions in ATYR, ALEC, BSX, CNTA, KALV, MREO, MRNA, NKTR, REGN, Sarepta Therapeutics. TGTX, RARE, VRNA, VRTX, BHVN, MRUS, IREN.
- Artia Global Partners was a net buyer of stock by $22M.
- Artia Global Partners has $706M in assets under management (AUM), dropping by 11.87%.
- Central Index Key (CIK): 0001937964
Tip: Access up to 7 years of quarterly data
Positions held by Artia Global Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Artia Global Partners
Artia Global Partners holds 50 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Insmed Com Par $.01 (INSM) | 27.2 | $192M | -2% | 1.1M | 174.04 |
|
| Abivax Sa Sponsored Ads (ABVX) | 11.7 | $82M | +170% | 611k | 134.85 |
|
| Argenx Se Sponsored Adr (ARGX) | 7.7 | $54M | -17% | 65k | 840.95 |
|
| Eli Lilly & Co. (LLY) | 7.7 | $54M | +75% | 51k | 1074.68 |
|
| Proshares Tr Ii Ultra Gold (UGL) | 4.3 | $30M | 542k | 55.52 |
|
|
| Soleno Therapeutics (SLNO) | 3.8 | $27M | -13% | 584k | 46.30 |
|
| Viking Therapeutics (VKTX) | 3.6 | $25M | +392% | 719k | 35.18 |
|
| Trevi Therapeutics (TRVI) | 3.6 | $25M | 2.0M | 12.52 |
|
|
| Uniqure Nv SHS (QURE) | 3.5 | $25M | +55% | 1.0M | 23.93 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 2.5 | $18M | +158% | 504k | 35.08 |
|
| Astrazeneca Sponsored Adr | 2.5 | $18M | 191k | 91.93 |
|
|
| Cidara Therapeutics Com New (CDTX) | 2.2 | $16M | NEW | 71k | 220.89 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 2.0 | $14M | +22% | 767k | 18.27 |
|
| Ionis Pharmaceuticals (IONS) | 1.6 | $11M | +139% | 144k | 79.11 |
|
| Dianthus Therapeutics (DNTH) | 1.2 | $8.5M | +88% | 205k | 41.21 |
|
| Revolution Medicines (RVMD) | 1.2 | $8.3M | 104k | 79.65 |
|
|
| Quest Diagnostics Incorporated (DGX) | 1.0 | $7.1M | -50% | 41k | 173.53 |
|
| Alnylam Pharmaceuticals (ALNY) | 1.0 | $6.9M | -49% | 17k | 397.65 |
|
| Ventyx Biosciences (VTYX) | 0.9 | $6.3M | NEW | 696k | 9.03 |
|
| Palvella Therapeutics Inc Ne (PVLA) | 0.9 | $6.2M | NEW | 59k | 104.67 |
|
| Mineralys Therapeutics (MLYS) | 0.7 | $5.0M | +143% | 138k | 36.29 |
|
| Sionna Therapeutics (SION) | 0.7 | $4.9M | NEW | 120k | 41.14 |
|
| Palisade Bio (PALI) | 0.7 | $4.7M | NEW | 2.0M | 2.35 |
|
| Avidity Biosciences Ord (RNA) | 0.6 | $4.3M | -45% | 60k | 72.13 |
|
| Scholar Rock Hldg Corp (SRRK) | 0.6 | $4.2M | 96k | 44.05 |
|
|
| Rapport Therapeutics (RAPP) | 0.6 | $4.2M | +114% | 139k | 30.34 |
|
| Prokidney Corp Shs Cl A (PROK) | 0.6 | $4.1M | NEW | 1.8M | 2.24 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.5 | $3.8M | +44% | 18k | 213.24 |
|
| Abbvie (ABBV) | 0.5 | $3.3M | 15k | 228.49 |
|
|
| Belite Bio Sponsored Ads (BLTE) | 0.4 | $2.9M | NEW | 18k | 159.96 |
|
| Roivant Sciences SHS (ROIV) | 0.4 | $2.8M | NEW | 130k | 21.70 |
|
| Ocular Therapeutix (OCUL) | 0.4 | $2.7M | +60% | 226k | 12.14 |
|
| Travere Therapeutics (TVTX) | 0.4 | $2.7M | +128% | 71k | 38.21 |
|
| Bright Minds Biosciences Com New (DRUG) | 0.4 | $2.6M | NEW | 33k | 78.04 |
|
| United Therapeutics Corporation (UTHR) | 0.3 | $2.4M | 5.0k | 487.25 |
|
|
| Protagonist Therapeutics (PTGX) | 0.3 | $2.0M | 23k | 87.34 |
|
|
| Upstream Bio (UPB) | 0.3 | $1.9M | NEW | 69k | 27.15 |
|
| Xenon Pharmaceuticals (XENE) | 0.3 | $1.8M | 40k | 44.82 |
|
|
| Bridgebio Pharma (BBIO) | 0.2 | $1.6M | 20k | 76.49 |
|
|
| Brightspring Health Svcs (BTSG) | 0.2 | $1.6M | 42k | 37.45 |
|
|
| Pepgen (PEPG) | 0.2 | $1.3M | NEW | 205k | 6.51 |
|
| Celcuity (CELC) | 0.2 | $1.3M | NEW | 13k | 99.74 |
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.2 | $1.2M | 29k | 41.25 |
|
|
| Nuvalent Inc-a (NUVL) | 0.1 | $815k | NEW | 8.1k | 100.59 |
|
| Avalo Therapeutics Com New (AVTX) | 0.1 | $755k | NEW | 42k | 18.16 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.1 | $737k | NEW | 2.5k | 294.74 |
|
| Alto Neuroscience Com Shs (ANRO) | 0.1 | $520k | NEW | 29k | 17.80 |
|
| Tenax Therapeutics Com New (TENX) | 0.1 | $513k | NEW | 42k | 12.19 |
|
| Kodiak Sciences (KOD) | 0.1 | $476k | NEW | 17k | 27.96 |
|
| Lyra Therapeutics Com New (LYRA) | 0.0 | $27k | NEW | 8.8k | 3.08 |
|
Past Filings by Artia Global Partners
SEC 13F filings are viewable for Artia Global Partners going back to 2022
- Artia Global Partners 2025 Q4 filed Feb. 17, 2026
- Artia Global Partners 2025 Q3 filed Nov. 14, 2025
- Artia Global Partners 2025 Q3 restated filed Nov. 14, 2025
- Artia Global Partners 2025 Q2 filed Aug. 14, 2025
- Artia Global Partners 2025 Q1 filed May 15, 2025
- Artia Global Partners 2024 Q4 filed Feb. 14, 2025
- Artia Global Partners 2024 Q3 filed Nov. 14, 2024
- Artia Global Partners 2024 Q2 filed Aug. 14, 2024
- Artia Global Partners 2024 Q1 filed May 15, 2024
- Artia Global Partners 2023 Q4 filed Feb. 14, 2024
- Artia Global Partners 2023 Q3 filed Nov. 14, 2023
- Artia Global Partners 2023 Q2 filed Aug. 14, 2023
- Artia Global Partners 2023 Q1 filed May 15, 2023
- Artia Global Partners 2022 Q4 filed Feb. 14, 2023